Piramal Pharma Limited announced its financial results for the second quarter (Q2) and half year (H1) ended 30th September 2024, delivering robust growth across key financial metrics.
Key Financial Highlights for Q2 FY25:
- Revenue from Operations: ₹2,242 crore, up 17% YoY from ₹1,911 crore in Q2 FY24, driven by strong performance in the CDMO segment.
- EBITDA: ₹403 crore, reflecting a 28% growth YoY, with an EBITDA margin of 18%, improving by 150 basis points YoY.
- PAT (Profit After Tax): ₹23 crore, a substantial increase of 350% YoY, compared to ₹5 crore in Q2 FY24.
- PAT Margin: 1%, steady compared to 0% in the previous year.
Segment Performance:
- CDMO (Contract Development and Manufacturing Organization): Revenue at ₹1,324 crore, up 24% YoY.
- CHG (Complex Hospital Generics): ₹643 crore, growing 9% YoY.
- ICH (India Consumer Healthcare): ₹277 crore, rising 8% YoY.
H1 FY25 Highlights:
- Revenue from Operations: ₹4,193 crore, a 15% increase YoY from ₹3,660 crore in H1 FY24.
- EBITDA: ₹627 crore, a growth of 29% YoY, with an EBITDA margin of 15%.
- PAT: Loss of ₹66 crore, compared to a loss of ₹94 crore in H1 FY24.
Additional Updates:
- Piramal Pharma released its FY2024 Sustainability Report, aligning with GRI standards and focusing on reducing greenhouse gas emissions in line with the SBTi’s 1.5-degree decarbonization pathway.
Piramal Pharma continues to strengthen its financial performance, driven by its diversified business model and operational efficiencies, particularly in the CDMO segment.
